Fig 1.
Representative schematic structure of ManLAM, Insert in the Blue box show residues adapted as strategic surrogates for LAM.
Fig 2.
Protocol for derivatization of D-Arabinose in urinary LAM and the corresponding mass fragmentation pattern.
Fig 3.
NMR spectra of anomeric protons and GC/MS peak ratio and different stereoisomeric forms of 2,3,5-trifluoroacetyl-1-(R-2-octyl)-arabinosyl glycosides.
Fig 4.
Differences in peak patterns and retention times in GC/MS chromatogram for D- and L- arabinose.
Fig 5.
D-Arabinose estimation of Non-Endemic-Urine (NEU).
1) Internal standard, 2) D-arabinose in NEU before purification; 3) D-arabinose not detected in NEU after purification.
Table 1.
FIND urine sample purification and D-arabinose analysis.
IS = Internal Standard; HIV = Human Immunodeficiency Virus; Pneu = Pneumonia; Atyp = Atypical TB,
Fig 6.
Protocol for TBSA detection by GC/MS.
Fig 7.
GC/MS chromatogram for TBSA detection in TBSSMC+ and TBSSMC- urine samples.
Table 2.
TBSA Based LAM Estimation of 29 Urine Samples (TBSSMC -, D-Arabinose/LAM positive).
Fig 8.
Summary of results for the GC/MS based urinary LAM detection on clinical samples.